{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:59:24Z","timestamp":1789610364361,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Project of State Key Laboratory of Oncogenes and Related Genes","award":["KF2419-93)"],"award-info":[{"award-number":["KF2419-93)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-53745-4","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:44:30Z","timestamp":1779284670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive risk model for bone metastasis in intermediate-risk prostate cancer: a single-center retrospective analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Jianfeng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feixiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianle","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"53745_CR1","first-page":"115","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen, W. et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66, 115\u2013132 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"53745_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia, G. et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur. Urol. 68, 325\u2013334 (2015).","journal-title":"Eur. Urol."},{"key":"53745_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"M N\u00f8rgaard","year":"2010","unstructured":"N\u00f8rgaard, M. et al. Skeletal Related Events, Bone Metastasis and Survival of Prostate Cancer: A Population Based Cohort Study in Denmark (1999 to 2007). J. Urol. 184, 162\u2013167 (2010).","journal-title":"J. Urol."},{"key":"53745_CR4","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/j.juro.2009.07.093","volume":"182","author":"KL Greene","year":"2009","unstructured":"Greene, K. L. et al. Prostate specific antigen best practice statement: 2009 update. J. Urol. 182, 2232\u20132241 (2009).","journal-title":"J. Urol."},{"key":"53745_CR5","doi-asserted-by":"publisher","first-page":"8266","DOI":"10.1007\/s00330-022-08945-7","volume":"32","author":"E Rud","year":"2022","unstructured":"Rud, E. et al. Validating the screening criteria for bone metastases in treatment-na\u00efve unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases. Eur. Radiol. 32, 8266\u20138275 (2022).","journal-title":"Eur. Radiol."},{"key":"53745_CR6","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","volume":"43","author":"G Shen","year":"2014","unstructured":"Shen, G., Deng, H., Hu, S. & Jia, Z. Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 43, 1503\u20131513 (2014).","journal-title":"Skeletal Radiol."},{"key":"53745_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet, N. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 71, 618\u2013629 (2017).","journal-title":"Eur. Urol."},{"key":"53745_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/bjc.2011.273","volume":"105","author":"P Kheirandish","year":"2011","unstructured":"Kheirandish, P. & Chinegwundoh, F. Ethnic differences in prostate cancer. Br. J. Cancer. 105, 481\u2013485 (2011).","journal-title":"Br. J. Cancer"},{"key":"53745_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/0972-3919.110683","volume":"27","author":"K Kamaleshwaran","year":"2012","unstructured":"Kamaleshwaran, K. et al. Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy. Indian J. Nucl. Med. 27, 81 (2012).","journal-title":"Indian J. Nucl. Med."},{"key":"53745_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","volume":"199","author":"MG Sanda","year":"2018","unstructured":"Sanda, M. G. et al. Clinically localized prostate cancer: AUA\/ASTRO\/SUO Guideline. Part I: Risk stratification, shared decision making, and care options. J. Urol. 199, 683\u2013690 (2018).","journal-title":"J. Urol."},{"key":"53745_CR11","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer, E. M. et al. Prostate cancer, Version 4.2023, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 21, 1067\u20131096 (2023).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"53745_CR12","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance, W. et al. Updates to advanced prostate cancer: AUA\/SUO Guideline (2023). J. Urol. 209, 1082\u20131090 (2023).","journal-title":"J. Urol."},{"key":"53745_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ygyno.2023.12.007","volume":"181","author":"S Nishio","year":"2024","unstructured":"Nishio, S. et al. Pretreatment systemic inflammatory markers predict survival in endometrial cancer: A Japanese Gynecologic Oncology Group 2043 exploratory data analysis. Gynecol. Oncol. 181, 46\u201353 (2024).","journal-title":"Gynecol. Oncol."},{"key":"53745_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/imm.13759","volume":"172","author":"Q Dong","year":"2024","unstructured":"Dong, Q. et al. The correlation between systemic inflammatory markers and efficiency for advanced gastric cancer patients treated with ICIs combined with chemotherapy. Immunology 172, 77\u201390 (2024).","journal-title":"Immunology"},{"key":"53745_CR15","doi-asserted-by":"publisher","first-page":"929572","DOI":"10.3389\/fendo.2022.929572","volume":"13","author":"D Aguilar-Cazares","year":"2022","unstructured":"Aguilar-Cazares, D. et al. The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment. Front. Endocrinol. 13, 929572 (2022).","journal-title":"Front. Endocrinol."},{"key":"53745_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12880-025-01642-z","volume":"25","author":"S Nie","year":"2025","unstructured":"Nie, S., Fan, B., Gui, S., Zou, H. & Lan, M. Predictive impact of T2-MRI radiomics model on initial diagnosis of bone metastasis in prostate cancer patients. BMC Med. Imaging. 25, 106 (2025).","journal-title":"BMC Med. Imaging"},{"key":"53745_CR17","doi-asserted-by":"publisher","first-page":"1626358","DOI":"10.3389\/fonc.2025.1626358","volume":"15","author":"X Chen","year":"2025","unstructured":"Chen, X. et al. The diagnostic value of inflammatory markers in bone metastasis of prostate cancer at initial prostate biopsy. Front. Oncol. 15, 1626358 (2025).","journal-title":"Front. Oncol."},{"key":"53745_CR18","doi-asserted-by":"publisher","first-page":"109020","DOI":"10.1016\/j.ejrad.2020.109020","volume":"128","author":"W Zhang","year":"2020","unstructured":"Zhang, W. et al. A radiomics nomogram for predicting bone metastasis in newly diagnosed prostate cancer patients. Eur. J. Radiol. 128, 109020 (2020).","journal-title":"Eur. J. Radiol."},{"key":"53745_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani, R. Regression shrinkage and selection via the Lasso. J. R Stat. Soc. Ser. B Stat. Methodol. 58, 267\u2013288 (1996).","journal-title":"J. R Stat. Soc. Ser. B Stat. Methodol."},{"key":"53745_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i11","volume":"36","author":"MB Kursa","year":"2010","unstructured":"Kursa, M. B. & Rudnicki, W. R. Feature selection with the Boruta package. J. Stat. Softw. 36, 1\u201313. https:\/\/doi.org\/10.18637\/jss.v036.i11 (2010).","journal-title":"J. Stat. Softw."},{"key":"53745_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00345-018-2390-8","volume":"37","author":"F Kum","year":"2019","unstructured":"Kum, F., Jones, A. & Nigam, R. Factors influencing urinary retention after transperineal template biopsy of the prostate: outcomes from a regional cancer centre. World J. Urol. 37, 337\u2013342 (2019).","journal-title":"World J. Urol."},{"key":"53745_CR22","doi-asserted-by":"publisher","first-page":"E59","DOI":"10.1111\/bju.13850","volume":"120","author":"GV KandaSwamy","year":"2017","unstructured":"KandaSwamy, G. V., Bennett, A., Narahari, K., Hughes, O., Kynaston, J. & Rees & Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer \u2013 results from a large contemporaneous cohort. BJU Int. 120, E59\u2013E63. https:\/\/doi.org\/10.1111\/bju.13850 (2017).","journal-title":"BJU Int."},{"key":"53745_CR23","first-page":"1016","volume":"43","author":"Genitourinary Oncology Committee of Chinese Anti-cancer Association","year":"2021","unstructured":"Genitourinary Oncology Committee of Chinese Anti-cancer Association. [Expert consensus on clinical diagnosis and treatment of bone metastases and bone-related diseases of prostate cancer (2021 edition)]. Zhonghua Zhong Liu Za Zhi. 43, 1016\u20131026 (2021).","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"53745_CR24","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/jnci\/djt175","volume":"105","author":"DV Makarov","year":"2013","unstructured":"Makarov, D. V. et al. Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging. JNCI J. Natl. Cancer Inst. 105, 1306\u20131313 (2013).","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"53745_CR25","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2012.42.8375","volume":"30","author":"LE Schnipper","year":"2012","unstructured":"Schnipper, L. E. et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J. Clin. Oncol. 30, 1715\u20131724 (2012).","journal-title":"J. Clin. Oncol."},{"key":"53745_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/pcan.2014.19","volume":"17","author":"SP Porten","year":"2014","unstructured":"Porten, S. P. et al. Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer Prostatic Dis. 17, 246\u2013251 (2014).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"53745_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00345-017-2096-3","volume":"36","author":"M Wondergem","year":"2018","unstructured":"Wondergem, M. et al. 99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET\/CT in primary staging of patients with prostate cancer. World J. Urol. 36, 27\u201334 (2018).","journal-title":"World J. Urol."},{"key":"53745_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.euf.2016.06.018","volume":"3","author":"AR Padhani","year":"2017","unstructured":"Padhani, A. R. et al. Rationale for modernising imaging in advanced prostate cancer. Eur. Urol. Focus. 3, 223\u2013239 (2017).","journal-title":"Eur. Urol. Focus"},{"key":"53745_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bju.14506","volume":"124","author":"PJ Van Leeuwen","year":"2019","unstructured":"Van Leeuwen, P. J. et al. Gallium-68\u2010prostate\u2010specific membrane antigen (68 Ga\u2010PSMA) positron emission tomography (PET)\/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate\u2010 and high\u2010risk prostate cancer. BJU Int. 124, 62\u201368 (2019).","journal-title":"BJU Int."},{"key":"53745_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","volume":"74","author":"S Siva","year":"2018","unstructured":"Siva, S. et al. Stereotactic Abative Body Radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur. Urol. 74, 455\u2013462 (2018).","journal-title":"Eur. Urol."},{"key":"53745_CR31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1259\/bjr\/79184355","volume":"85","author":"C Mcarthur","year":"2012","unstructured":"Mcarthur, C., Mclaughlin, G. & Meddings, R. N. Changing the referral criteria for bone scan in newly diagnosed prostate cancer patients. Br. J. Radiol. 85, 390\u2013394 (2012).","journal-title":"Br. J. Radiol."},{"key":"53745_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.1993.03500010067033","volume":"269","author":"JE Oesterling","year":"1993","unstructured":"Oesterling, J. E., Martin, S. K., Bergstralh, E. J. & Lowe, F. C. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269, 57\u201360 (1993).","journal-title":"JAMA"},{"key":"53745_CR33","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.urology.2006.02.009","volume":"68","author":"A Salonia","year":"2006","unstructured":"Salonia, A. et al. Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features. Urology 68, 362\u2013366 (2006).","journal-title":"Urology"},{"key":"53745_CR34","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/jcsm.13032","volume":"13","author":"M Song","year":"2022","unstructured":"Song, M. et al. The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer. J. Cachexia Sarcopenia Muscle. 13, 2504\u20132514 (2022).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"53745_CR35","doi-asserted-by":"publisher","first-page":"BSR20200352","DOI":"10.1042\/BSR20200352","volume":"40","author":"X Yan","year":"2020","unstructured":"Yan, X. & Li, G. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer. Biosci. Rep. 40, BSR20200352 (2020).","journal-title":"Biosci. Rep."},{"key":"53745_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.21037\/atm.2019.08.116","volume":"7","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis. Ann. Transl Med. 7, 433\u2013433 (2019).","journal-title":"Ann. Transl Med."},{"key":"53745_CR37","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.breast.2015.09.007","volume":"24","author":"J Wen","year":"2015","unstructured":"Wen, J. et al. The preoperative plasma fibrinogen level is an independent prognostic factor for overall survival of breast cancer patients who underwent surgical treatment. Breast 24, 745\u2013750 (2015).","journal-title":"Breast"},{"key":"53745_CR38","doi-asserted-by":"publisher","first-page":"e993","DOI":"10.6061\/clinics\/2020\/e993","volume":"75","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer. Clinics 75, e993 (2020).","journal-title":"Clinics"},{"key":"53745_CR39","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.ctrv.2015.10.002","volume":"41","author":"C Perisanidis","year":"2015","unstructured":"Perisanidis, C. et al. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat. Rev. 41, 960\u2013970 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"53745_CR40","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s40001-023-01562-0","volume":"28","author":"Z Yu","year":"2023","unstructured":"Yu, Z., Yuan, M. & Chen, G. The clinical association between coagulation indexes, platelet-related parameters, and bone metastasis of newly diagnosed prostate cancer. Eur. J. Med. Res. 28, 587 (2023).","journal-title":"Eur. J. Med. Res."},{"key":"53745_CR41","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1097\/CM9.0000000000000506","volume":"132","author":"GS Xie","year":"2019","unstructured":"Xie, G. S. et al. Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients. Chin Med. J. (Engl). 132, 2684\u20132689 (2019).","journal-title":"Chin Med. J. (Engl)"},{"key":"53745_CR42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/10408363.2016.1200008","volume":"53","author":"XR Xu","year":"2016","unstructured":"Xu, X. R. et al. Platelets are versatile cells: New discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond. Crit. Rev. Clin. Lab. Sci. 53, 409\u2013430 (2016).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"53745_CR43","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","volume":"91","author":"JJ Caro","year":"2001","unstructured":"Caro, J. J., Salas, M., Ward, A. & Goss, G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91, 2214\u20132221 (2001).","journal-title":"Cancer"},{"key":"53745_CR44","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1158\/0008-5472.CAN-20-1994","volume":"81","author":"CH Liu","year":"2021","unstructured":"Liu, C. H. et al. Lipopolysaccharide-mediated chronic inflammation promotes tobacco carcinogen\u2013induced lung cancer and determines the efficacy of immunotherapy. Cancer Res. 81, 144\u2013157 (2021).","journal-title":"Cancer Res."},{"key":"53745_CR45","doi-asserted-by":"publisher","first-page":"bqab254","DOI":"10.1210\/endocr\/bqab254","volume":"163","author":"JM Siegfried","year":"2022","unstructured":"Siegfried, J. M. Sex and gender differences in lung cancer and chronic obstructive lung disease. Endocrinology 163, bqab254 (2022).","journal-title":"Endocrinology"},{"key":"53745_CR46","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.eururo.2009.12.023","volume":"5b7","author":"A Briganti","year":"2010","unstructured":"Briganti, A. et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur. Urol. 5b7, 551\u2013558 (2010).","journal-title":"Eur. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53745-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53745-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53745-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:17:48Z","timestamp":1784762268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53745-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53745"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53745-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving human subjects was approved by the Medical Ethics Review Committee of the First People\u2019s Hospital of Nantong (2022KT100).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was waived for this retrospective study with deidentified data, in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23032"}}